<DOC>
	<DOCNO>NCT02218190</DOCNO>
	<brief_summary>The purpose study determine Alvimopan reduce incidence post operative ileus patient undergo posterior spinal fusion .</brief_summary>
	<brief_title>Alvimopan Ileus PSF</brief_title>
	<detailed_description>Posterior spinal fusion ( PSF ) common orthopaedic procedure associate high incidence post-operative ileus ( POI ) concomitant increase length hospital stay ( LOHS ) . POI exacerbate high dose opiate consumption often required patient post-operatively . We propose randomize , double-blinded , placebo-controlled pilot trial study use alvimopan , peripherally-acting mu-opioid receptor antagonist know reduce POI bowel resection . We hypothesize alvimopan shorten POI spine fusion patient without negatively affect post-operative pain control . Treatment efficacy assess record time first bowel movement , time hospital discharge , post-operative pain control . We hypothesize acute administration alvimopan , peripherally-acting mu-opioid antagonist , shorten duration post-operative ileus ( POI ) patient undergo long-segment ( 5 great thoracolumbar level ) posterior spinal fusion ( PSF ) . The study randomize , double-blinded , placebo-controlled pilot trial . Reducing morbidity POI patient undergo PSF decrease hospital stay cost , also improve patient satisfaction post-operative care major orthopaedic surgery .</detailed_description>
	<mesh_term>Ileus</mesh_term>
	<mesh_term>Alvimopan</mesh_term>
	<criteria>adult patient undergo elective PSF least 5 level and/or fixation pelvis pregnant woman ischemic heart disease chronic liver renal disease prior bowel resection presence colostomy ileostomy gastroparesis complete bowel obstruction inflammatory bowel disease ( ulcerative colitis Crohn 's disease ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Alvimopan</keyword>
	<keyword>Ileus</keyword>
	<keyword>Posterior spinal fusion</keyword>
</DOC>